# Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

Source: https://onco.cc/trials/nct06938867/  
OnCo record `nct06938867` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli in advanced solid tumours, run by SNIPR Biome Aps., now recruiting.

## Summary

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant is a phase 1/2 interventional study registered as NCT06938867 by SNIPR Biome Aps., with 24 participants planned, started 2025-02-25 and due to reach its primary completion in 2026-04-01. Interventions recorded: SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06938867
- Phase: 1/2
- Setting: A Phase 1b/2a, Randomized, Double-blind Study to Investigate Safety, Tolerability, PK, PD, and Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplantation Receiving Fluoroquinolone Prophylaxis and Harboring Fluoroquinolone-Resistant Escherichia Coli Pre-Transplant
- Sponsor: SNIPR Biome Aps.
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT06938867: https://clinicaltrials.gov/study/NCT06938867

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06938867.json